Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort.
ABSTRACT Mutations in the FUS gene on chromosome 16 have been recently discovered as a cause of familial amyotrophic lateral sclerosis (FALS). This study determined the frequency and identities of FUS gene mutations in a cohort of Italian patients with FALS.
We screened all 15 coding exons of FUS for mutations in 94 Italian patients with FALS.
We identified 4 distinct missense mutations in 5 patients; 2 were novel. The mutations were not present in 376 healthy Italian controls and thus are likely to be pathogenic.
Our results demonstrate that FUS mutations cause approximately 4% of familial amyotrophic lateral sclerosis cases in the Italian population.
- SourceAvailable from: Teepu Siddique[Show abstract] [Hide abstract]
ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disorder caused by degeneration of motor neurons. Mutations in the FUS gene were identified in patients with familial ALS (FALS) and patients with sporadic ALS (SALS) from a variety of genetic backgrounds. This work further explores the spectrum of FUS mutations in patients with FALS and patients with FALS with features of frontotemporal dementia (FALS/FTD) or parkinsonism and dementia (FALS/PD/DE). All exons of the FUS gene were sequenced in 476 FALS index cases negative for mutations in SOD1 and TARDBP. A total of 561-726 controls were analyzed for genetic variants observed. Clinical data from patients with FUS mutations were compared to those of patients with known SOD1 and TARDBP mutations. We identified 17 FUS mutations in 22 FALS families, 2 FALS/FTD families, and 1 FALS/PD/DE family from diverse genetic backgrounds; 11 mutations were novel. There were 4 frameshift, 1 nonsense, and 1 possible alternate splicing mutation. Patients with FUS mutations appeared to have earlier symptom onset, a higher rate of bulbar onset, and shorter duration of symptoms than those with SOD1 mutations. FUS gene mutations are not an uncommon cause in patients with FALS from diverse genetic backgrounds, and have a prevalence of 5.6% in non-SOD1 and non-TARDBP FALS, and approximately 4.79% in all FALS. The pathogenicity of some of these novel mutations awaits further studies. Patients with FUS mutations manifest earlier symptom onset, a higher rate of bulbar onset, and shorter duration of symptoms.Neurology 08/2010; 75(9):807-14. · 8.30 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Neurodegenerative diseases are a growing public health challenge, and amyotrophic lateral sclerosis (ALS) remains a fatal incurable disease. The advent of stem cell therapy has opened new horizons for both researchers and ALS patients, desperately looking for a treatment. ALS must be considered a systemic disease affecting many cell phenotypes besides motor neurons, even outside the central nervous system. Cell replacement therapy needs to address the specific neurobiological issues of ALS to safely and efficiently reach clinical settings. Moreover, the enormous potential of induced pluripotent cells directly derived from patients for modeling and understanding the pathological mechanisms, in correlation with the discoveries of new genes and animal models, provides new opportunities that need to be integrated with previously described transplantation strategies. Finally, a careful evaluation of preclinical data in conjunction with wary patient choice in clinical trials needs to be established in order to generate meaningful results.Stem Cells and Cloning: Advances and Applications 01/2010; 3:145-156.
- [Show abstract] [Hide abstract]
ABSTRACT: Parkinson's disease (PD) is a movement disorder that afflicts over one million in the U.S.; amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is less prevalent but also has a high incidence. The two disorders sometimes present together, making a comparative study of interest. Both ALS and PD are neurodegenerative diseases, and are characterized by the presence of intraneuronal inclusions; however, different classes of neurons are affected and the primary protein in the inclusions differs between the diseases, and in some cases is different in distinct forms of the same disease. These observations might suggest that the more general approach of proteostasis pathway alteration would be a powerful one in treating these disorders. Examining results from human genetics and studies in model organisms, as well as from biochemical and biophysical characterization of the proteins involved in both diseases, we find that most instances of PD can be considered as arising from the misfolding, and self-association to a toxic species, of the small neuronal protein α-synuclein, and that proteostasis strategies are likely to be of value for this disorder. For ALS, the situation is much more complex and less clear-cut; the available data are most consistent with a view that ALS may actually be a family of disorders, presenting similarly but arising from distinct and nonoverlapping causes, including mislocalization of some properly folded proteins and derangement of RNA quality control pathways. Applying proteostasis approaches to this disease may require rethinking or broadening the concept of what proteostasis means.Cold Spring Harbor perspectives in biology 08/2011; 3(10):a007500. · 9.63 Impact Factor
Analysis of FUS gene mutation in familial
amyotrophic lateral sclerosis within an
N. Ticozzi, MD
V. Silani, MD
A.L. LeClerc, BA
P. Keagle, BS
C. Gellera, PhD
A. Ratti, PhD
F. Taroni, MD
P.C. Sapp, BS
R.H. Brown, Jr., MD,
J.E. Landers, PhD
Objective: Mutations in the FUS gene on chromosome 16 have been recently discovered as a
cause of familial amyotrophic lateral sclerosis (FALS). This study determined the frequency and
identities of FUS gene mutations in a cohort of Italian patients with FALS.
Methods: We screened all 15 coding exons of FUS for mutations in 94 Italian patients with FALS.
Results: We identified 4 distinct missense mutations in 5 patients; 2 were novel. The mutations
were not present in 376 healthy Italian controls and thus are likely to be pathogenic.
Conclusions: Our results demonstrate that FUS mutations cause ?4% of familial amyotrophic
lateral sclerosis cases in the Italian population. Neurology®2009;73:1180–1185
ALS ? amyotrophic lateral sclerosis; FALS ? familial amyotrophic lateral sclerosis; FTD ? frontotemporal dementia; gDNA ?
genomic DNA; LMN ? lower motor neuron; NLS ? nuclear localization signal; UMN ? upper motor neuron.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of adult life characterized by
a selective loss of upper motor neurons (UMN) and lower motor neurons (LMN). The cause of
the disease is largely unknown. Approximately 10% of all ALS cases are familial (FALS), of
which ?20% are caused by mutations in the SOD1 gene.1Variants in TARDBP, which
encodes the DNA/RNA binding protein TDP-43, account for an additional ?5% of cases.2-4
Pathogenic mutations in 5 other genes (ALS2, SETX, VAPB, DNCT1, and ANG) have also
been associated with atypical ALS phenotypes in isolated families.5,6Recently, mutations in the
FUS gene, which also encodes a DNA/RNA binding protein, have been identified in ?5% of
patients with FALS who tested negative for SOD1 and TARDBP mutations.7,8The similarities
between TARDBP and FUS suggest that alterations in RNA processing may play an important
role in ALS pathogenesis. The FUS gene was initially isolated analyzing chromosomal translo-
cations in myxoid liposarcoma9and subsequently found in a variety of cancer-associated fusion
genes. The protein plays a role in transcription, splicing,10and shuttling of RNA from the
nucleus to the cytoplasm.11FUS also acts as a transcriptional regulatory sensor of DNA damage
signals and thus is required in maintaining the integrity of the genome.12FUS is diffusely
expressed in the CNS where it regulates the morphology of hippocampal dendritic spines and
stabilizes the structure of the synapse.13To further define the frequency and spectrum of FUS
mutations, we have screened a cohort of Italian patients with FALS.
e-Pub ahead of print on September 9, 2009, at www.neurology.org.
From the Department of Neurology (N.T., A.L.L., P.K., D.M.M.-Y., P.C.S., R.H.B., J.E.L.), University of Massachusetts Medical School, Worcester;
Department of Neurology and Laboratory of Neuroscience (N.T., V.S., A.R.), Centro “Dino Ferrari,” Universita ` degli Studi di Milano-IRCCS
Istituto Auxologico Italiano, Milan; Unit of Genetics of Neurodegenerative and Metabolic Diseases (C.G., F.T.), Fondazione IRCCS Istituto
Neurologico “Carlo Besta,” Milan, Italy; Department of Neurology (T.J.K.), Massachusetts General Hospital, Boston; and Howard Hughes Medical
Institute and Department of Biology (P.C.S.), Massachusetts Institute of Technology, Cambridge.
Supported by the ALS Therapy Alliance, Project ALS, the Angel Fund, the Pierre L. de Bourgknecht ALS Research Foundation, the Al-Athel ALS
Research Foundation, the ALS Family Charitable Foundation, and the National Institute of Neurological Disorders and Stroke (NS050557 and
NS050641). N.T., V.S., and A.R. were supported by the Italian Ministry of Health (Malattie Neurodegenerative, ex Art.56, n.533F/N1). F.T. and
C.G. were supported by the Italian Ministry of Health grant RF2007/INN644440. P.S. was supported by the Howard Hughes Medical Institute
(HHMI) through the auspices of Prof. H. Robert Horvitz, an Investigator in the HHMI. R.H.B. is a cofounder of AviTx, which targets development
Disclosure: Author disclosures are provided at the end of the article.
Editorial, page 1172
Address correspondence and
reprint requests to Dr. John E.
Landers, LRB604, 364 Plantation
St., Worcester, MA 01605
Copyright © 2009 by AAN Enterprises, Inc.
METHODS Patients and controls. Peripheral blood sam-
ples were collected from 94 unrelated patients with FALS (53
men and 41 women) in the period between 2002 and 2007. All
the patients were of Italian descent and were diagnosed with
probable or definite ALS according to the El Escorial revised
criteria.14Familial history was considered positive for ALS if the
proband had at least 1 affected relative within 3 generations. The
disease onset was bulbar in 24% of patients and spinal in 76%.
Six patients (4 men and 2 women) developed frontotemporal
dementia (FTD). In agreement with previous epidemiologic sur-
veys on motor neuron disease in Italy,15an initial involvement
of bulbar motor neurons was slightly more frequent in
women (30%) than men (19%). The average age at onset in
our cohort was 46.8 ? 15.2 years. Mutations in SOD1,
ANG,16and TARDBP17were excluded in all samples in the
present study. Control DNA was obtained from 376 unre-
lated, age-matched Italian subjects with a negative personal
and familial history for neurodegenerative diseases.
Standard protocol approvals, registrations, and patient
consents. We received approval for this study from the ethical
standards committees on human experimentation of the IRCCS
Istituto Auxologico Italiano and of the Fondazione IRCCS Isti-
tuto Neurologico “Carlo Besta.” Written informed consent was
obtained from all patients and healthy subjects participating in
the study (consent for research).
Molecular analysis. Genomic DNA (gDNA) was extracted
from peripheral blood leukocytes using standard procedures and
was subsequently amplified using the IllustraTMGenomiPhi HY
DNA Amplification Kit (GE Healthcare Life Sciences, Little Chal-
FUS were amplified by touchdown PCR using primers located in
adjacent intronic or noncoding regions. PCR primers and condi-
tions have been described elsewhere.7PCR products were subse-
quently purified by incubation with Exonuclease I and Shrimp
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and
then resolved by capillary electrophoresis on an ABI 3730XL DNA
Analyzer (Applied Biosystems). Sequence analysis was per-
formed using the PHRED/PHRAP/Consed software suite
(www.phrap.org/phredphrapconsed.html),18-21and variations in
the sequences were identified with the Polyphred v6.15 software
mutations were further confirmed by bidirectional sequencing of
the original gDNA sample. The screening of the c.701G?T
mutation in control samples was performed using a custom Taq-
Man SNP Genotyping Assay using the File Builder 3.1 software
(Applied Biosystems) which consisted of a mix of unlabeled PCR
forward and reverse primers (forward: 5?-GCGGCGGTGGT-
GGTT-3?; reverse: 5?-CACGACCTCTGGGTTCATAGC-3?)
and 2 dye-labeled probes (allele X: VIC-CACTGCTGCGGT-
TGT-NFQ; allele Y: FAM-CACTGCTGAGGTTGT-NFQ).
Since the TaqMan assay designed for the c.467G?A mutation
failed to generate consistent results, exon 5 of the FUS gene was
directly sequenced in all control samples.
Bioinformatic analysis. The effect on splicing of the non-
coding and synonymous variants identified was assessed using
the electronic tools ESEfinder 3.0 (http://rulai.cshl.edu/tools/
html),25and SpliceView (http://bioinfo.itb.cnr.it/oriel/splice-
view.html).26In silico prediction of the putative functional ef-
fects of the missense mutations was obtained with the SNAP
RESULTS To identify novel FUS mutations and
further define the frequency of all FUS gene variants
in FALS, we sequenced the coding region (exons
1–15) and the intron/exon boundaries in 94 FALS
samples of Italian descent. Our sequence analysis
identified 2 previously described missense mutations
in the FUS gene. The mutation c.1561C?T pro-
duces an arginine to cysteine change at amino acid
521 (p.R521C) and was observed in 2 patients. The
c.1561C?G mutation was identified in a single pa-
tient and alters the same base pair but changes the
arginine residue to a glycine (p.R521G). In addition,
we have identified 2 novel missense mutations. The
mutation c.467G?A was identified in a single pa-
tient; it changes a glycine to a glutamic acid at posi-
tion 156 (p.G156E). The mutation c.701G?T, also
identified in a single patient, changes an arginine res-
idue to a leucine at position 234 (p.R234L). The
pedigrees of the patients carrying FUS mutations are
shown in figure 1. Chromatograms displaying the
mutations are shown in figure e-1 on the Neurology®
Web site at www.neurology.org. Unfortunately,
since all the affected relatives of the probands are
deceased, we could not evaluate the segregation of
the mutations in families. In addition to the missense
mutations, we also identified a novel synonymous
substitution (c.1566G?A [p.R522R]) as well as 5
novel variants in intronic (c.832 ? 36A?G,
c.833 ? 29C?T, c.1066 ? 82C?G) and 3? UTR
(c.*10C?T, c.*41G?A) regions of FUS (table e-1).
In silico analysis with the ESEfinder 3.0 software
showed that the synonymous variant does not dis-
rupt any exonic splicing enhancer motif, while
NNSplice and SpliceView programs predicted that
the intronic and 3? UTR variants do not affect splic-
ing mechanisms. These variants were not further
To determine whether the 2 novel missense muta-
tions are low allele frequency polymorphisms in the
population, we genotyped the p.G156E and
p.R234L mutations on a panel of 376 healthy con-
trol samples of Italian descent. Neither variant was
identified in these normal controls. This finding
strongly argues that these missense variants represent
The p.G156E is located within the SYQG do-
main of the FUS protein, which acts as a transcrip-
tional activation domain. Additionally, the p.R234L
mutation is located within the G-rich domain, a re-
gion in which 3 mutations have previously been
reported (figure 2). To further evaluate the pathoge-
nicity of these novel mutations, we used 2 software
Neurology 73October 13, 2009
applications, PMut and SNAP, which predict
whether a missense mutation is pathogenic or be-
nign. As expected, the previously described muta-
tions (p.R521C and p.R521G) were predicted to be
deleterious by both PMut and SNAP (table). The
novel mutations p.G156E and p.R234L are similarly
predicted to be deleterious by both PMut and SNAP
(table). In support of this prediction, we note that
the residues affected by these mutations (G156 and
R234) are highly conserved, being present in mam-
mals, reptiles, and zebra fish (figure 3). This observa-
tion also supports the view that the corresponding
missense mutations are adverse and likely to be
Phenotypic information for the 5 patients carry-
ing FUS mutations is provided in the table. Detailed
clinical records were available for 3 (B303, A51, and
B153) of the 5 patients and other affected family
members, and are reported in appendix e-1. Patient
B303 harbors the p.G156E mutation whereas both
A51 and B153 have the p.R521C mutation. Nota-
bly, each affected individual in the 3 pedigrees devel-
oped early symptoms of symmetric weakness of the
scapular or pelvic girdles and of the proximal muscles
of the upper or lower limbs. Also prominent was the
involvement of the axial muscles of the neck and
In total, we have identified 5 missense mutations
within a panel of 94 Italian patients with FALS
which were prescreened and found not to have muta-
tions in the SOD1 and TARDBP genes (which repre-
sent ?25% of all FALS cases). We therefore estimate
Figure 2Location of FUS mutations in familial amyotrophic lateral sclerosis
indicate the exons where mutations have been identified. (B) Linear protein structure of FUS indicating the different do-
mains. Amino acid changes are shown above the protein with arrows indicating their position. Mutations found in Italian
patients are shown in red.
Figure 1 Pedigrees of familial amyotrophic lateral sclerosis cases harboring FUS mutations
This illustrates the structure of the 5 unrelated Italian pedigrees to which the 5 cases studied here belong. Affected
individuals are shown in black; unaffected individuals are shown in white. Arrows indicate the individual harboring the
Neurology 73 October 13, 2009
that ?4% of FALS cases within the Italian popula-
tion are caused by mutation in the FUS gene. This
frequency is similar to that reported in a recent
screening in another FALS cohort.29
DISCUSSION FUS mutations were initially identi-
fied in 20 cases of FALS.7,8A vast majority of the
alterations (16 out of 20) were missense mutations
clustered in 5 arginine residues located in exon 15 of
the FUS gene. Interestingly, a p.H517Q homozy-
gous mutation within exon 15 was found in a family
presenting a recessive inheritance pattern; all other
identified families displayed a dominant inheritance
pattern. Additional mutations were identified in
exon 5 (p.174–175insGG, p.173–174delGG), exon
6 (p.R244C), and exon 14 (p.R514G). The pre-
dicted amino acid sequence of the FUS protein is
highly evolutionarily conserved and consists of an
N-terminal SYQG-rich region that acts as a tran-
scriptional activation domain, two G-rich regions, an
RNA binding domain, a Cys2/Cys2-zinc finger mo-
tif, and a C-terminal RGG-rich region, which con-
tains the nuclear localization signal (NLS).30,31
In our cohort of 94 unrelated Italian patients with
FALS, we identified FUS mutations in 5 patients.
The observed mutational frequency in our Italian co-
hort is similar to that observed in the 2 previous stud-
ies of FUS mutations in ALS.7,8Previous mutational
screenings have suggested that the prevalence of
SOD1 mutations in Italian ALS families is about
15%.32,33ANG mutations account for ?2% of
all familial cases,16while a recent study identified
TARDBP mutations in 6 out of 125 Italian patients
with FALS (4.8%).17To date, in the Italian popula-
tion, mutations in the ALS2 gene have been reported
only in an handful of families affected by infantile
ascending hereditary spastic paralysis34or juvenile
primary lateral sclerosis,35while a screening for
VAPB variants in patients with ALS was negative.36
To our knowledge, there are no reports of SETX or
dynactin mutations in Italian patients with ALS. Our
findings thus suggest that FUS mutations represent
the third most significant cause of FALS in Italy after
SOD1 and TARDBP.
In our cohort, we found 2 previously identified
mutations, p.R521G and p.R521C. The substitution
of the arginine at codon 521 disrupts the NLS and
leads to an aberrant subcellular distribution of FUS,
with retention and apparent aggregation of the mu-
tant protein in the cytoplasm.7The 2 novel muta-
tions observed in our cohort are located in the
N-terminal SYQG-rich domain (p.G156E) and in
the first G-rich region (p.R234L), where other muta-
tions have been found7(figure 2B). No data are avail-
able on the functional role of these variants, since
they are not located in the NLS and thus presumably
do not alter the subcellular localization of FUS.
Moreover, very little information is available on the
activity of both the SYQG-rich and G-rich domain
of FUS. We hypothesize, however, that p.G156E
and p.R234L are pathogenic for several reasons. The
amino acids at these positions are highly evolutionar-
ily conserved (figure 3) and these variants were not
detected in 376 Italian healthy controls (752 chro-
mosomes). Finally, both in silico SNAP and PMut
software analyses predicted that p.G156E and
p.R234L affect protein function (table), although
these data should be interpreted with caution.
Figure 3Evolutionary conservation of FUS mutations
The evolutionary conservation of all 4 identified mutations is shown. For each, the mutated
amino acid is shown in red.
Table Phenotypic description of patients with FUS mutations
M c.467G?A G156E5 33 Bulbar11 UMN/LMN Yes Pathogenic Non-neutral
F c.701G?TR234L6 66Spinal N/AN/A NoPathogenic Non-neutral
Mc.1561C?T R521C 15 32Bulbar11 LMNNo Pathogenic Non-neutral
F c.1561C?T R521C15 25 Spinal60 LMNNoPathogenic Non-neutral
F c.1561C?G R521G15n/aSpinalN/AN/ANo Pathogenic Non-neutral
UMN/LMN ? presence of both upper and lower motor neuron signs; LMN ? prevalence of lower motor neuron signs; N/A ?
Neurology 73October 13, 2009
We note that the clinical presentation of the Ital-
ian patients with FUS gene mutations (symmetric,
proximal, and axial weakness at onset) was distinct
from typical ALS, which often begins in a single limb
distally.37Severe weakness of neck extensor muscles
at onset, as seen in one Italian case, is present in only
about 1% of patients with ALS,38and thus is also
unusual. We also note that in his fourth decade, pa-
tient B303 (p.G156E mutation) developed FTD
concurrently with motor neuron disease; patients
with ALS in the 2 previous reports on FUS muta-
tions were not described as having concomitant de-
mentia. It will be of interest to determine whether
FUS mutations consistently correlate with these dis-
tinctive clinical phenotypes in other patients with
Given the complexity of cellular functions and
pathways in which FUS is involved, further studies
will be required to delineate the explicit mechanisms
whereby these FUS mutations cause motor neuron
death. In particular, it will be of interest to assess
if the pathogenic pathways involving FUS and
TARDBP overlap. The 2 genes encode for DNA/
RNA binding proteins involved in gene regulation
and RNA processing. Mutations in FUS and TARDBP
may alter the binding of their nucleic acid targets,
resulting in altered mRNA splicing. Additionally,
some mutations have been shown to impair the capa-
bility of both proteins to shuttle between the nucleus
and the cytoplasm.39Widespread defects in RNA
processing as a result of either, or both, of these
mechanisms could lead to motor neuron death. The
precise pathogenic mechanism notwithstanding, our
study provides strong evidence that mutations in the
FUS gene represent a significant cause of familial
ALS in the Italian population. It also suggests that
some patients carrying FUS mutations may have un-
common clinical phenotypes, a possibility that mer-
its further analysis as more opportunities arise to
correlate FUS genotypes with clinical phenotypes.
Writing team: N.T., V.S., A.L., P.K, R.H.B., J.L.; all others received and
approved the manuscript. Patient selection, preliminary genetic screening,
and record collection: N.T., V.S., A.R., C.G., F.T., P.S. Sequencing and
genotyping: N.T., A.L., P.K. Data analysis: N.T., V.S., R.H.B., J.E.L.
Scientific planning and direction: N.T., V.S., A.L., T.K., R.H.B., J.E.L.
The authors thank the Italian patients with ALS and their caregivers and
the Peviani family for support.
Dr. Ticozzi has received research support from the Italian Ministry of
Health (Malattie Neurodegenerative, ex Art. 56, n533F/N1). Dr. Silani
serves on the editorial advisory boards of Amyotrophic Lateral Sclerosis,
European Neurology, and the Journal of Pediatric Neurology, and receives
research support from the Italian Ministry of Health (Malattie Neurode-
generative, ex Art. 56, n533F/N1). A.L. Leclerc and P. Keagle report no
disclosures. Dr. Gellera has received research support from the Italian
Ministry of Health (#RF2007/INN644440). Dr. Ratti has received re-
search support from the Italian Ministry of Health (Malattie Neurodegen-
erative, ex Art. 56, n533F/N1). Dr. Taroni serves on the scientific
advisory board of the Italian Ataxia Association (AISA); serves on the
editorial board of the Journal of Neurology; and receives research support
from ApoPharma Inc. [EudraCT No. 2007-003331-23 and No. 2009-
010865-22 (Unit PI)], the Telethon Foundation (Telethon and
Telethon-UILDM Project Coordinator), and the Italian Ministry of
Health [AIFA EudraCT No. 2007-003357-85 (PI) and MoH RF2007/
INN644440)]. Dr. Kwiatkowski has served as consultant and received
funding for international travel from Asia Ventures Management; receives
license fee payments as a contributor to US Patents 5,741,645 (issued:
1998) and 5,834,183 (issued: 1998) entitled “Gene sequence for spino-
cerebellar ataxia type 1 and method for diagnosis” and may accrue revenue
from US patent 61/135,689, “Genetic test for FUS ALS” (filed: 2008);
has served as consultant and received honoraria from Athena Diagnostics,
Inc.; and receives research support from the NIH [R01NS050557 (Co-PI)]
and from the ALS Therapy Alliance, the Angel Fund and Project ALS,
the Pierre L. de Bourgknecht ALS Research Foundation, the Al-Athel
ALS Research Foundation, and the ALS Family Charitable Foundation.
D.M. McKenna-Yasek receives salary support from the NIH [RO1-
NS050641-04]. P.C. Sapp has received research support from the
Howard Hughes Medical Institute (grant awarded to Prof. H. Robert
Horvitz). Dr. Brown serves on scientific advisory boards for Biogen Idec,
Acceleron Pharma, Link Medicine, and AviTx Inc.; has filed/holds US
Patent 5,843,641, “Methods for the diagnosis of familial amyotrophic
lateral sclerosis” (filed: 1993); receives royalties from publishing Principles
of Neurology (McGraw-Hill, 2005); receives research support from the
NIH [NINDS R01NS050557 (PI) and NINDS UO1NS052225-02
(PI)], the ALS Therapy Alliance, Project ALS, the Angel Fund, the Pierre
L. de Bourgknecht ALS Research Foundation, the Al-Athel ALS Research
Foundation, and the ALS Family Charitable Foundation; receives board
of directors compensation from AviTx Inc. (co-founder); and receives
license fee payments from Athena Diagnostics, Inc. related to diagnostic
blood tests. Dr. Landers has received payments from MIT as an inventor
of US Patent 6,703,228; has been deposed concerning a lawsuit between
Affymetrix, Inc. and E8/MIT regarding this patent; and has received re-
search support from the ALS Therapy Alliance, Project ALS, the Angel
Fund, the Pierre L. de Bourgknecht ALS Research Foundation, the Al-
Athel ALS Research Foundation, and the ALS Family Charitable Founda-
tion. His spouse is an employee of Bristol-Myers Squibb.
Received March 19, 2009. Accepted in final form July 1, 2009.
1. Rosen DR, Siddique T, Patterson D, et al. Mutations in
Cu/Zn superoxide dismutase gene are associated with fa-
milial amyotrophic lateral sclerosis. Nature 1993;362:
2.Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 muta-
tions in familial and sporadic amyotrophic lateral sclerosis.
3.Kabashi E, Valdmanis PN, Dion P, et al. TARDBP muta-
tions in individuals with sporadic and familial amyotro-
phic lateral sclerosis. Nat Genet 2008;40:572–574.
4.Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP
mutations in amyotrophic lateral sclerosis with TDP-43
neuropathology: a genetic and histopathological analysis.
Lancet Neurol 2008;7:409–416.
5. Pasinelli P, Brown RH. Molecular biology of amyotrophic
lateral sclerosis: insights from genetics. Nat Rev Neurosci
6.Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyo-
trophic lateral sclerosis: controversies and perspectives.
Amyotroph Lateral Scler 2009;10:1–14.
7.Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Muta-
tions in the FUS/TLS gene on chromosome 16 cause fa-
Neurology 73October 13, 2009
milial amyotrophic lateral sclerosis. Science 2009;323:
Vance C, Rogelj B, Hortobagyi T, et al. Mutations in
FUS, an RNA processing protein, cause familial amyotro-
phic lateral sclerosis type 6. Science 2009;323:1208–1211.
Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP
to a novel RNA-binding protein in human myxoid liposar-
coma. Nature 1993;363:640–644.
Yang L, Embree LJ, Tsai S, Hickstein DD. Oncoprotein
TLS interacts with serine-arginine proteins involved in
RNA splicing. J Biol Chem 1998;273:27761–27764.
Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS
(FUS) binds RNA in vivo and engages in nucleo-
cytoplasmic shuttling. J Cell Sci 1997;110(Pt 15):1741–
Wang X, Arai S, Song X, et al. Induced ncRNAs allosteri-
cally modify RNA-binding proteins in cis to inhibit tran-
scription. Nature 2008;454:126–130.
Fujii R, Okabe S, Urushido T, et al. The RNA binding
protein TLS is translocated to dendritic spines by mGluR5
activation and regulates spine morphology. Curr Biol
Miller RG, Munsat TL, Swash M, Brooks BR. Consensus
guidelines for the design and implementation of clinical
trials in ALS: World Federation of Neurology committee
on Research. J Neurol Sci 1999;169:2–12.
Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G.
Incidence of ALS in Lombardy, Italy. Neurology 2007;68:
Gellera C, Colombrita C, Ticozzi N, et al. Identification of
new ANG gene mutations in a large cohort of Italian pa-
tients with amyotrophic lateral sclerosis. Neurogenetics
Corrado L, Ratti A, Gellera C, et al. High frequency of
TARDBP gene mutations in Italian patients with amyo-
trophic lateral sclerosis. Hum Mutat 2009;30:688–694.
Ewing B, Hillier L, Wendl MC, Green P. Base-calling of
automated sequencer traces using phred: I: accuracy assess-
ment. Genome Res 1998;8:175–185.
Ewing B, Green P. Base-calling of automated sequencer
traces using phred II: error probabilities. Genome Res
Gordon D, Desmarais C, Green P. Automated finishing
with autofinish. Genome Res 2001;11:614–625.
Gordon D, Abajian C, Green P. Consed: a graphical tool
for sequence finishing. Genome Res 1998;8:195–202.
Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automat-
ing the detection and genotyping of single nucleotide sub-
stitutions using fluorescence-based resequencing. Nucleic
Acids Res 1997;25:2745–2751.
Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ,
Krainer AR. An increased specificity score matrix for the
prediction of SF2/ASF-specific exonic splicing enhancers.
Hum Mol Genet 2006;15:2490–2508.
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR.
ESEfinder: a web resource to identify exonic splicing en-
hancers. Nucleic Acids Res 2003;31:3568–3571.
Reese MG, Eeckman FH, Kulp D, Haussler D. Improved
splice site detection in Genie. J Comput Biol 1997;4:311–
Rogozin IB, Milanesi L. Analysis of donor splice sites in dif-
ferent eukaryotic organisms. J Mol Evol 1997;45:50–59.
Bromberg Y, Rost B. SNAP: predict effect of non-
synonymous polymorphisms on function. Nucleic Acids
Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la
Cruz X, Orozco M. PMUT: a web-based tool for the an-
notation of pathological mutations on proteins. Bioinfor-
Chiò A, Restagno G, Brunetti M, et al. Two Italian kin-
dreds with familial amyotrophic lateral sclerosis due to
FUS mutation. Neurobiol Aging 2009;30:1272–1275.
Morohoshi F, Ootsuka Y, Arai K, et al. Genomic structure
of the human RBP56/hTAFII68 and FUS/TLS genes.
Zakaryan RP, Gehring H. Identification and characteriza-
tion of the nuclear localization/retention signal in the
EWS proto-oncoprotein. J Mol Biol 2006;363:27–38.
Gellera C, Castellotti B, Riggio MC, et al. Superoxide dis-
mutase gene mutations in Italian patients with familial and
sporadic amyotrophic lateral sclerosis: identification of
three novel missense mutations. Neuromuscul Disord
Battistini S, Giannini F, Greco G, et al. SOD1 mutations
in amyotrophic lateral sclerosis. Results from a multicenter
Italian study J Neurol 2005;252:782–788.
Lesca G, Eymard-Pierre E, Santorelli FM, et al. Infantile
ascending hereditary spastic paralysis (IAHSP): clinical fea-
tures in 11 families. Neurology 2003;60:674–682.
Panzeri C, De Palma C, Martinuzzi A, et al. The first
ALS2 missense mutation associated with JPLS reveals new
aspects of alsin biological function. Brain 2006;129:1710–
Conforti FL, Sprovieri T, Mazzei R, et al. Sporadic ALS is
not associated with VAPB gene mutations in Southern It-
aly. J Negat Results Biomed 2006;5:7.
Ravits J, Paul P, Jorg C. Focality of upper and lower motor
neuron degeneration at the clinical onset of ALS. Neurol-
Gourie-Devi M, Nalini A, Sandhya S. Early or late appear-
ance of “dropped head syndrome” in amyotrophic lateral
sclerosis. J Neurol Neurosurg Psychiatry 2003;74:683–686.
Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the
FUS about TDP-43. Cell 2009;136:1001–1004.
Neurology 73 October 13, 2009